China-based Tot Biopharma International Co., Ltd (HKG: 1875) has announced a strategic partnership with compatriot firm GL-Biotech in relation to GL-Biotech’s proprietary DisacLink technology. The collaboration aims to achieve technological breakthroughs, jointly develop, improve, and commercialize fixed-point conjugate technology, with both parties engaging in extensive commercial cooperation for the external promotion of this technology. Additionally, GL-Bio has granted Tot Bio rights to carry out Contract Development and Manufacturing Organization (CDMO) services with the DisacLink platform.
Enhancing ADC Homogeneity and Stability with DisacLink Technology
Traditional antibody drug conjugates (ADCs) face challenges with poor homogeneity and low stability due to the use of the amino group of antibody lysine or the sulfhydryl group of cysteine obtained by opening the disulfide bond between chains for coupling. This affects the efficacy and treatment window of ADCs. To address these issues, researchers have developed a site-specific coupling method using cysteine, glutamine, unnatural amino acids, short peptide tags, and polysaccharides. This method allows for the coupling of cytotoxic or chemotherapy drugs to specific locations within the antibody molecule, resulting in ADCs with high uniformity, good stability, better activity, and improved pharmacokinetic characteristics.
GL-Biotech’s Focus on Fixed ADC Drug Development
Founded in 2021, GL-Bio is dedicated to the research and development of fixed ADC drugs, with a focus on the oncology field. The company’s commitment to innovation in ADC technology positions it at the forefront of cancer treatment advancements.-Fineline Info & Tech
